leflunomide / Generic mfg. 
Welcome,         Profile    Billing    Logout  
 88 Diseases   68 Trials   68 Trials   2888 News 


«12...7891011121314151617...3536»
  • ||||||||||  montelukast / Generic mfg.
    New P2 trial:  Montelukast Use in Rheumatoid Arthritis (clinicaltrials.gov) -  Jul 7, 2022   
    P2,  N=50, Not yet recruiting, 
  • ||||||||||  prednisone / Generic mfg., leflunomide / Generic mfg.
    Enrollment open, Trial completion date, Trial primary completion date:  TACTIC: Takayasu Arteritis Clinical Trial in China (clinicaltrials.gov) -  Jun 28, 2022   
    P=N/A,  N=116, Recruiting, 
    This systematic literature review informed the initiative to formulate EULAR 'points to consider' on COVID-19 pathophysiology and immunomodulatory treatment from the rheumatology perspective. Unknown status --> Recruiting | Trial completion date: Jun 2020 --> Dec 2022 | Trial primary completion date: Dec 2019 --> Dec 2022
  • ||||||||||  teriflunomide / Generic mfg.
    Teriflunomide associated alopecia areata - a case report (e-Poster Hall) -  Jun 13, 2022 - Abstract #EADVSp2022EADV_Sp_350;    
    In conclusion, the identification teriflunomide and leflunomide as potential triggers for AA, and their discontinuation may result in remission of the disease. On the other hand, although the association between AA and MS is not defined, due to their shared pathogenetic processes, close attention to MS signs and symptoms must be given in patients affected by AA.
  • ||||||||||  leflunomide / Generic mfg.
    Journal:  Leflunomide-Induced Liver Injury: Differences in Characteristics and Outcomes in Indian and US Registries. (Pubmed Central) -  Jun 11, 2022   
    Leflunomide hepatotoxicity is more likely accompanied by SCAR, a short latency and a higher mortality in the Indian cohort, with a predominance of females, compared to US DILIN patients. The differences in skin involvement, immunoallergic features and outcomes among subjects from India vs. the USA suggest that genetic or environmental factors are important in the pathogenesis of liver injury.
  • ||||||||||  cyclosporine / Generic mfg., leflunomide / Generic mfg.
    Journal, Adverse events:  Seroprevalence of SARS-CoV-2-specific antibodies and vaccination-related adverse events in systemic lupus erythematosus and rheumatoid arthritis. (Pubmed Central) -  Jun 8, 2022   
    The differences in skin involvement, immunoallergic features and outcomes among subjects from India vs. the USA suggest that genetic or environmental factors are important in the pathogenesis of liver injury. Our study reveals that the seroprevalences of IgG and IgM antibodies against SARS-CoV-2 and vaccination-related adverse effects are similar among SLE, RA and HCs, suggesting that COVID-19 vaccine is safe and effective for SLE and RA patients to prevent from the pandemic of COVID-19.
  • ||||||||||  leflunomide / Generic mfg.
    Enrollment closed, Enrollment change, Trial primary completion date:  Leflunomide for the Treatment of Relapsed or Refractory CD30+ Lymphoproliferative Disorders (clinicaltrials.gov) -  Jun 8, 2022   
    P2,  N=1, Active, not recruiting, 
    Our study reveals that the seroprevalences of IgG and IgM antibodies against SARS-CoV-2 and vaccination-related adverse effects are similar among SLE, RA and HCs, suggesting that COVID-19 vaccine is safe and effective for SLE and RA patients to prevent from the pandemic of COVID-19. Recruiting --> Active, not recruiting | N=12 --> 1 | Trial primary completion date: Jul 2023 --> Aug 2022
  • ||||||||||  Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
    Journal:  Expert Perspective: An Approach to Refractory Lupus Nephritis. (Pubmed Central) -  Jun 4, 2022   
    For patients who have LN that is truly refractory to standard of care, B cell-targeted therapy, specifically rituximab (RTX), is the most common next step. No abstract available
  • ||||||||||  CoronaVac / Sinovac, Bio Farma Indonesia, Comirnaty (tozinameran) / Pfizer, Fosun Pharma, BioNTech, Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
    Journal:  Strong response after 4th dose of mRNA COVID-19 vaccine in autoimmune rheumatic diseases patients with poor response to inactivated vaccine. (Pubmed Central) -  Jun 4, 2022   
    P4
    This is the largest study to provide evidence of a remarkable humoral response after the 4th dose of heterologous mRNA SARS-CoV-2 vaccination in ARD patients with poor/no-response to the 3rd dose of an inactivated vaccine. We further identified that treatment, particularly rituximab and prednisone, impaired antibody response to this additional dose.
  • ||||||||||  leflunomide / Generic mfg.
    Preclinical, Journal:  The Anti-Rheumatic Drug, Leflunomide, Induces Nephrotoxicity in Mice via Upregulation of TGFβ-Mediated p53/Smad2/3 Signaling. (Pubmed Central) -  May 29, 2022   
    This toxicity is mediated through stimulating fibrotic changes through TGFβ-stimulated p53/Smad2/3 signaling and induction of glomerular and tubular apoptosis. An improved understanding of LEFN-induced nephrotoxicity would have great implications in the prediction, prevention, and management of leflunomide-treated rheumatic patients, and may warrant further clinical studies for following up these toxidromes.
  • ||||||||||  Taltz (ixekizumab) / Eli Lilly, Japan Tobacco, Stelara (ustekinumab) / J&J, Xeljanz (tofacitinib) / Pfizer
    ASSESSMENT OF THE SENSITIVITY OF THE RUSSIAN VERSION OF PSAID-12 QUESTIONNAIRE () -  May 24, 2022 - Abstract #EULAR2022EULAR_4412;    
    All pts at the time of inclusion in the study and 12mo received DMARDs: NSAIDs-158 (91.8%), methotrexate -134 (77.9%), leflunomide- 11 (6.3%), sulfasalazine - 12 (6.9%), TNFα inhibitors - 72 (44.04%), sekukinumab -14 (8.1%), ustekinumab -3 (1.74%), ixekizumab - 1 (0.58%), apremilast- 16 (9.3%), tofacitinib - 51 (29.1%). The russian version of the PsAID-12 questionnaire reflects the dynamics depending on the activity of the disease during treatment, which proves its good sensitivity.
  • ||||||||||  ALL-CAUSE MORTALITY IN PATIENTS WITH PALINDROMIC RHEUMATISM: A POPULATION-BASED COHORT STUDY () -  May 24, 2022 - Abstract #EULAR2022EULAR_4401;    
    Potential confounders included age, sex, CCI, a history of immune mediated inflammatory disease (IMID) including systemic lupus erythematosus erythematosus (SLE), RA, idiopathic inflammatory myopathies (IIM, including dermatomyositis and polymyositis), Sjögren’s syndrome (SS), inflammatory bowel disease (IBD), psoriasis, and medication use including corticosteroid (0, 1-5, >5 mg/day prednisolone equivalent dose), methotrexate, sulfasalazine, leflunomide, hydroxychloroquine and nonsteroidal anti-inflammatory drugs within one year before the index date. This population-based cohort study showed that the all-cause mortaltiy rate in PR patients was lower than that in non-PR individuals, in particular in subjects without a history of IMIDs.
  • ||||||||||  INCREASED RISK OF HEPATOTOXICITY WITH DMARDS IN PATIENTS WITH PREVIOUS LIVER TOXICITY WITH ISONIAZID. STUDY IN A SINGLE UNIVERSITY HOSPITAL () -  May 24, 2022 - Abstract #EULAR2022EULAR_4244;    
    ABA: Abatacept; AZA: Azathioprine, HCQ: Hydroxychloroquine; INH: Isoniazid; LFN: Leflunomide; MMF: Mycophenolate mofetil, MTX: Methotrexate; PsA: Psoriatic arthritis, RA: Rheumatoid arthritis, RTX: Rituximab; SpA: Axial spondyloarthritis; SSc: Systemic sclerosis; TCZ: Tocilizumab; TNFi: TNF inhibitors * Patients with higher liver enzyme elevation are included in the previous groups...Hepatotoxicity was not observed with hydroxychloroquine, azathioprine, mycophenolate mofetil, secukinumab, abatacept or rituximab... In patients with previous hepatotoxicity with INH, we observed an increased risk with different DMARDs, especially with MTX.
  • ||||||||||  Actemra IV (tocilizumab) / Roche, JW Pharma, Kineret (anakinra) / SOBI, Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
    ACUTE PERICARDITIS IN TIMES OF COVID () -  May 24, 2022 - Abstract #EULAR2022EULAR_4119;    
    The possibility of a correlation with COVID19 or vaccination against COVID was initially considered, but it could not be demonstrated, since vaccination was later in vaccinated patients, and in those who had been infected, the time interval until the development of pericarditis was too long for it in order to be attributed to COVID19. Finally, in 5 of the 8 patients, pericarditis was related to SAD, in particular with the rheumatic pathologies most associated with this clinical manifestation (RA and SLE).
  • ||||||||||  Remicade (infliximab) / Merck (MSD), Mitsubishi Tanabe, J&J, Humira (adalimumab) / Eisai, AbbVie
    POSTER: SARS-COV 2 INFECTION AND ANTI TNF THERAPY IN RHEUMATOID ARTHRITIS PATIENTS () -  May 24, 2022 - Abstract #EULAR2022EULAR_4105;    
    TNF blockers in monotheraphy or associated with Methotrexate were correlated with lower odds of hospitalization and milder forms of COVID-19. No significant difference of hospitalization odd was observed between vaccinated and unvaccinated patients.
  • ||||||||||  prednisone / Generic mfg., methotrexate / Generic mfg., leflunomide / Generic mfg.
    MAINTENANCE THERAPY FOR PATIENTS WITH RHEUMATIC DISEASES DURING THE COVID-19 () -  May 24, 2022 - Abstract #EULAR2022EULAR_4061;    
    Our work showed that the maintenance of conventional treatment during Covid-19 infection was associated with a lower risk of severe forms. Our results, along with those of other studies in the literature, support the maintenance of antirheumatic treatments.
  • ||||||||||  Sputnik-V (Gam-COVID-Vac Lyo) / Gamaleya Research Institute
    SAFETY OF COVID-19 VACCINES IN PATIENTS WITH RHEUMATOID ARTHRITIS (PRELIMINARY DATA). () -  May 24, 2022 - Abstract #EULAR2022EULAR_4026;    
    According to preliminary data, the tolerance of vaccines against COVID-19 in RA patients is satisfactory. Further studies are needed to study the safety, immunogenicity and clinical efficacy of immunization against COVID-19 in patients of this cohort.
  • ||||||||||  Remicade (infliximab) / Merck (MSD), Mitsubishi Tanabe, J&J, CoronaVac / Sinovac, Bio Farma Indonesia, Humira (adalimumab) / Eisai, AbbVie
    COVID-19 VACCINATION OF SPONDYLOARTHRITIS PATIENTS RECEIVING BIOLOGICAL THERAPY: REAL-LIFE DATA () -  May 24, 2022 - Abstract #EULAR2022EULAR_4021;    
    During the follow-up of the patients during the study, no major vaccine-related side effects, post-vaccine disease activation and the need for treatment change were not detected. In order to more accurately evaluate the efficacy of the vaccination program in the patient population using biologic agents, larger-scale studies including unvaccinated individuals are needed.
  • ||||||||||  Tremfya (guselkumab) / J&J
    EFFECTIVENESS OF GUSELKUMAB IN PSORIATIC ARTHRITIS IN DAILY CLINICAL PRACTISE () -  May 24, 2022 - Abstract #EULAR2022EULAR_3883;    
    Guselkumab is a very effective drug for the treatment of psoriasis, but also for the joint involvement in patients with failure to bDMARD. We need more real life studies to determinate the effectiveness in daily clinical practise.
  • ||||||||||  methotrexate / Generic mfg., leflunomide / Generic mfg.
    A temporary antirheumatic drugs withdrawal does not cause an excess of disease flares in patients with psoriatic arthritis undergoing Covid-19 mRNA vaccination () -  May 24, 2022 - Abstract #EULAR2022EULAR_3863;    
    Methotrexate (MTX) and leflunomide were withheld 7 days after each dose, whilst biological DMARDs (bDMARDs), were either continued (46.8% of the patients) or withheld (53.2%) from the day of the first dose until 7 days after the second dose. Our findings suggest that a temporary short halt of bDMARDs could be a viable option in patients with well-controlled PsA undergoing Covid-19 vaccination without increasing the risk of flares, which could be useful to increase T cell response and antibody titres after Covid-19 vaccination.